e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
William W. Busse, Guy G. Brusselle, Stephanie Korn, Piotr Kuna, Antoine Magnan, David Cohen, Karin Bowen, Teresa Piechowiak, Millie M. Wang, Gene Colice
Source:
Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
William W. Busse, Guy G. Brusselle, Stephanie Korn, Piotr Kuna, Antoine Magnan, David Cohen, Karin Bowen, Teresa Piechowiak, Millie M. Wang, Gene Colice. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma
Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019
Year: 2020
Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Source: International Congress 2017 – Asthma management
Year: 2017
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003
Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 541s
Year: 2004
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019
Year: 2020
To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009
The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005
Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept